One class of these cancer specific agents which have entered preclinical studies are so called SMAC-mimetics which are designed to inhibit the inhibitor-of-apoptosis protein members BIRC2/ cIAP1, BIRC3/cIAP2 and BIRC4/XIAP 17. Here, XIAP is linked to cancer.